Edesa Biotech, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2022. The filing is unaudited and reports in U.S. dollars. Edesa is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-related diseases; it has not generated significant revenue.
Financial performance and position
- Revenue and margins: No significant product revenue was reported. Grant reimbursements are recorded as other income, not operating revenue; conventional revenue margins are therefore not meaningful.
- Quarter: Operating expenses were $4.58 million, including R&D of $3.04 million and G&A of $1.53 million. Net loss was $4.57 million, or $0.33 per share, versus a $2.26 million loss, or $0.19 per share, a year earlier.
- Six months: Operating expenses were $9.74 million, including R&D of $6.99 million and G&A of $2.74 million. Net loss was $8.95 million, or $0.66 per share, versus a $4.90 million loss, or $0.45 per share.
- Cash flow: Operating cash use was $3.62 million for the six months, compared with $10.19 million in the prior-year period. Financing provided $11.63 million; cash increased by $8.05 million to $15.89 million.
- Liquidity and liabilities: Current assets were $18.00 million and current liabilities $3.34 million, yielding working capital of approximately $14.66 million. Total liabilities were $3.38 million, primarily accounts payable and lease obligations; the filing reports no borrowings. Total assets were $20.41 million and shareholders’ equity $17.02 million.
- Share count: 15,462,287 common shares were outstanding at March 31, 2022, compared with 13,295,403 at September 30, 2021. A further 1,199,727 pre-funded warrant shares and 2,739,727 common warrant shares were issued in the March financing, in addition to placement-agent warrants.
Changes and notable items
- Quarterly R&D expense fell $4.94 million year over year, primarily because of lower milestone and drug-substance payments, license fees, and external research costs. Six-month R&D fell $2.36 million; higher external research, manufacturing, and personnel costs partly offset the decrease.
- Grant income declined sharply: none was recorded in the current quarter versus $7.17 million in the prior-year quarter. For the six months, grant income was $0.78 million versus $7.17 million. The filing attributes the decrease to completion of clinical-study activities eligible under the Canadian Strategic Innovation Fund (SIF) grant.
- On March 24, 2022, Edesa completed an offering of common shares and pre-funded warrants, alongside common share purchase warrants. Gross proceeds were approximately $10.0 million and net proceeds approximately $9.01 million. The company also received approximately $2.62 million net from sales under its at-the-market program before terminating that program on March 21, 2022.
- EB05, being studied for COVID-19-related ARDS, was described as progressing to a Phase 3 confirmatory trial after an independent monitoring board identified a “clinically important” mortality benefit in the Phase 2 portion. EB01, for chronic allergic contact dermatitis, was in a Phase 2b study.
Outlook, risks, and commitments
- Management planned to fund operations over the next 12 months with cash on hand and reimbursements of eligible R&D expenses under the SIF agreement. It also expects to seek additional financing; the filing cautions that funding may not be available on acceptable terms. No specific operating or earnings guidance was provided.
- Management expects continued operating losses as clinical development proceeds. Study costs may fluctuate with trial initiation and patient recruitment. COVID-19 developments could affect operations, clinical timelines, and financial results.
- Contracted research and other commitments totaled approximately $4.33 million at March 31, 2022. License agreements also carry contingent milestone obligations of up to $352.5 million and $68.9 million, plus potential royalties or other payments; these are not current fixed debt obligations.
- The company had $1.1 million of SIF grant reimbursements receivable. It reported no material legal proceedings outside the ordinary course and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective as of March 31, 2022.
Most important facts for investors to verify
- Timing and amount of remaining SIF reimbursements, grant eligibility, and collection of the $1.1 million receivable.
- Clinical progress and subsequent results for EB05 and EB01, including whether EB05’s Phase 3 trial proceeds as expected.
- Cash burn, clinical commitments, and whether available cash and planned reimbursements support operations beyond management’s stated 12-month plan.
- Potential dilution from the March 2022 warrants and other equity compensation or financing activity.
- Terms and triggering conditions for the substantial contingent license milestones and royalties.